Vigil Neuroscience (VIGL) has made great progress in being able to advance its pipeline. It just reported interim results from its phase 2 IGNITE study, which used its drug iluzanebart [formerly ...
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback